Context Capital Management, LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 49 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
Context Capital Management, LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2022$4,280
-100.0%
4,323
-68.4%
0.31%
-62.9%
Q1 2022$12,984,000
+47.9%
13,667
+48.1%
0.84%
+23.2%
Q4 2021$8,777,000
-31.2%
9,227
-34.8%
0.68%
-47.4%
Q3 2021$12,753,000
+25.4%
14,142
+25.4%
1.30%
+38.2%
Q2 2021$10,168,000
-9.4%
11,279
-17.8%
0.94%
-14.4%
Q1 2021$11,229,000
+46.4%
13,714
-99.9%
1.10%
+5.0%
Q4 2020$7,671,000
-39.6%
9,887,000
-37.4%
1.05%
-62.0%
Q3 2020$12,702,000
+9.9%
15,799,000
+2.9%
2.76%
-38.6%
Q2 2020$11,558,000
+142.9%
15,359,000
+162.1%
4.50%
+66.4%
Q1 2020$4,758,000
+752.7%
5,859,000
+959.5%
2.70%
+864.6%
Q4 2019$558,000
+29.8%
553,000
+10.6%
0.28%
+14.8%
Q3 2019$430,000
-53.6%
500,000
-50.0%
0.24%
-53.3%
Q4 2018$926,000
-80.9%
1,000,000
-79.2%
0.52%
-81.4%
Q3 2018$4,843,000
+900.6%
4,800,000
-12.7%
2.82%
+577.2%
Q2 2018$484,000
-82.7%
5,500,000
+83.3%
0.42%
-81.4%
Q1 2017$2,804,000
-32.8%
3,000,000
-35.5%
2.24%
-51.0%
Q4 2016$4,173,000
-34.1%
4,650,000
-17.7%
4.57%
-25.8%
Q3 2016$6,335,0005,650,0006.16%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2020
NameSharesValueWeighting ↓
Silver Point Capital L.P. 57,420,000$44,527,0005.17%
Birch Grove Capital LP 10,003,000$7,934,0004.14%
PenderFund Capital Management Ltd. 9,605,000$9,491,0002.41%
Context Capital Management, LLC 9,887,000$7,671,0001.05%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$45,738,0000.90%
DeepCurrents Investment Group LLC 35,892,000$27,953,0000.74%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 22,977,000$18,267,0000.70%
WHITEBOX ADVISORS LLC 23,150,000$17,847,0000.56%
ADVENT CAPITAL MANAGEMENT /DE/ 27,397,000$21,720,0000.46%
OAKTREE CAPITAL MANAGEMENT LP 19,435,000$15,079,0000.26%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders